Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Daniel A. Petro"'
Autor:
Salehe S. Mandai, Filbert Francis, Daniel P. Challe, Misago D. Seth, Rashid A. Madebe, Daniel A. Petro, Rule Budodo, Angelina J. Kisambale, Gervas A. Chacha, Ramadhan Moshi, Ruth B. Mbwambo, Dativa Pereus, Catherine Bakari, Sijenunu Aaron, Daniel Mbwambo, Abdallah Lusasi, Stella Kajange, Samuel Lazaro, Ntuli Kapologwe, Celine I. Mandara, Deus S. Ishengoma
Publikováno v:
Malaria Journal, Vol 23, Iss 1, Pp 1-18 (2024)
Abstract Background Although Tanzania adopted and has been implementing effective interventions to control and eventually eliminate malaria, the disease is still a leading public health problem, and the country experiences heterogeneous transmission.
Externí odkaz:
https://doaj.org/article/7bb4cba687fe42178407e475d4d828a0
Autor:
Mike Gart, Rushir J. Choksi, Daniel P. Petro, Jeffrey A. Scott, Prateesh Varughese, Matt Stockton, Robert E. Smith
Publikováno v:
Journal of Clinical Oncology. 40:304-304
e13507 Background: In August 2019 IC partnered with University of Pittsburg Medical Center (UPMC) on a QI aimed at improving outcomes in stages 3 and 4 NSCLC. This report details the findings, interventions, and results in the stage 4 cohort to date.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::084b29f88e4519e1a3ee6d66b96d1f74
https://doi.org/10.1200/jco.2022.40.28_suppl.304
https://doi.org/10.1200/jco.2022.40.28_suppl.304
Autor:
Mike Gart, Lucio N. Gordan, Rushir J. Choksi, Daniel P. Petro, Jeffrey A. Scott, Prateesh Varughese, Erin Alwon, Robert E. Smith
Publikováno v:
Journal of Clinical Oncology. 40:e13510-e13510
e13510 Background: Broad molecular profile-based initiation of Tx in newly diagnosed NSCLC 4 (KF Mileham, Cancer Med, 2022) is advocated by NCCN guidelines. Despite this, Tx is often started prior to, and without knowledge of, an actionable oncogenic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fc42dbb4923d536d2e66d63d4630d10f
https://doi.org/10.1200/jco.2022.40.16_suppl.e13510
https://doi.org/10.1200/jco.2022.40.16_suppl.e13510
Autor:
Mark A. Socinski, Athanassios Argiris, Jill M. Siegfried, Theofanis Floros, Sanja Dacic, Imran Rafique, Jose Gomez-Garcia, Timothy F. Burns, Daniel P. Petro, Phu Tran, Laura P. Stabile, David M. Friedland, Ahmad A. Tarhini, Mariya Farooqui, Autumn Gaither-Davis, William E. Gooding, Liza C. Villaruz
Publikováno v:
Cancer. 123:2936-2944
BACKGROUND Activation of the mesenchymal-epidermal transition factor (MET) tyrosine kinase and its ligand, hepatocyte growth factor (HGF), is implicated in resistance to epidermal growth factor receptor (EGFR) inhibitors. In this phase 1/2 trial, ril
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12aae335ac34379d95a87a5f94b1070b
https://doi.org/10.1002/cncr.30717
https://doi.org/10.1002/cncr.30717
Autor:
Jieling Miao, Noman M. Rafique, David R. Gandara, Kathy S. Albain, Saiama N. Waqar, Eric C. McGary, Roy S. Herbst, Daniel P. Petro, Martin J. Edelman, Vassiliki A. Papadimitrakopoulou, Karen Kelly, Katherine Minichiello, Mary W. Redman
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, vol 14, iss 10
ObjectiveLung-MAP (SWOG S1400) is a master platform trial assessing targeted therapies in squamous NSCLC. Theobjective of study C (S1400C) was to evaluate the response rate to palbociclib, a cyclin-dependent kinase 4and cyclin-dependent kinase 6 inhi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77210407997f059f1fe2ad68a3b4988d
https://escholarship.org/uc/item/55d8p8f8
https://escholarship.org/uc/item/55d8p8f8
Autor:
Leonard Joseph Appleman, Marie Pouquet, Ronald G. Stoller, Hussein Tawbi, Sandra Strychor, David R. Gandara, Suresh S. Ramalingam, Alice P. Chen, R. Donald Harvey, Jan H. Beumer, Shannon Puhalla, Taofeek K. Owonikoko, Edward Chu, Yan Lin, Fei Ding, Athanassios Argiris, Brian F. Kiesel, Leigh Swartz, Yixing Jiang, Chandra P. Belani, Daniel P. Petro
Publikováno v:
Cancer Chemother Pharmacol
PURPOSE: Veliparib is an oral inhibitor of poly(ADP-ribose) polymerase (PARP)-1 and −2. PARP-1 expression may be increased in cancer, and this increase confers resistance to cytotoxic agents. We aimed to determine the recommended phase 2 dose (RP2D
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e3e023be893c965032cd5cab3e31847
https://pubmed.ncbi.nlm.nih.gov/31549216
https://pubmed.ncbi.nlm.nih.gov/31549216
Autor:
Robert E. Smith, Mike Gart, Jeffrey A. Scott, Prateesh Varughese, Daniel P. Petro, Elvis Marshall, Rebecca Tarlazzi, Elizabeth Botts, Greg Brown, Sarah Quatela, Sandy English, Hinco J. Gierman, Monica Labrador, Rushir J. Choksi
Publikováno v:
Journal of Clinical Oncology. 39:e18780-e18780
e18780 Background:In August 2019 Integra Connect (IC) partnered on a QI with University of Pittsburgh Medical Center (UPMC) to improve outcomes in patients with stage 3 and 4 NSCLC. This report details the findings and interventions in the unresectab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bf9290ec58e5b8598ee7ee023c4f9f6a
https://doi.org/10.1200/jco.2021.39.15_suppl.e18780
https://doi.org/10.1200/jco.2021.39.15_suppl.e18780
Autor:
Hong Wang, Ronny Kalash, Alina Mihai, Philip A. Sutera, Steven A. Burton, Dwight E. Heron, David J. D'Ambrosio, Daniel P. Petro, David A. Clump
Publikováno v:
International journal of radiation oncology, biology, physics. 103(1)
Purpose Oligometastatic disease has emerged as a potentially curable state in the spectrum of cancer progression. Aggressive local therapy such as stereotactic ablative radiation therapy (SABR) may improve oncologic outcomes. Herein, we report the in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b879781a8c5495b39cf75a0e79d70ff2
https://pubmed.ncbi.nlm.nih.gov/30149056
https://pubmed.ncbi.nlm.nih.gov/30149056
Autor:
Shannon Puhalla, Leonard Joseph Appleman, John C. Schmitz, Fei Ding, Pamela A. Hershberger, Benedito A. Carneiro, Yan Lin, Chandra P. Belani, Alice P. Chen, Madani Rachid, Jan H. Beumer, Brian F. Kiesel, Yixing Jiang, Daniel P. Petro, R. Ken Czambel, Emmanuel Kontopodis, Salah Almokadem, Edward Chu, Julianne L. Holleran, Ronald G. Stoller
Publikováno v:
Cancer chemotherapy and pharmacology. 80(3)
Veliparib (ABT-888) is an oral PARP inhibitor expected to increase gemcitabine activity. This phase I determined the maximal tolerable dose (MTD), dose-limiting toxicities (DLT), antitumor activity, pharmacokinetics (PK), and pharmacodynamics (PD) of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92b862a67e9720b22c04be4891547c5f
https://pubmed.ncbi.nlm.nih.gov/28770300
https://pubmed.ncbi.nlm.nih.gov/28770300
Autor:
Ahmad A, Tarhini, Imran, Rafique, Theofanis, Floros, Phu, Tran, William E, Gooding, Liza C, Villaruz, Timothy F, Burns, David M, Friedland, Daniel P, Petro, Mariya, Farooqui, Jose, Gomez-Garcia, Autumn, Gaither-Davis, Sanja, Dacic, Athanassios, Argiris, Mark A, Socinski, Laura P, Stabile, Jill M, Siegfried
Publikováno v:
Cancer. 123(15)
Activation of the mesenchymal-epidermal transition factor (MET) tyrosine kinase and its ligand, hepatocyte growth factor (HGF), is implicated in resistance to epidermal growth factor receptor (EGFR) inhibitors. In this phase 1/2 trial, rilotumumab (a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::abea6e5a6b0c8b4740392bf893e19bd3
https://pubmed.ncbi.nlm.nih.gov/28472534
https://pubmed.ncbi.nlm.nih.gov/28472534